IHA Daily Briefing: March 13

It's Patient Safety Awareness Week
IDPH, CDC Issue Warning on Stem Cell Therapies
IHA Issues Hospital-Specific VBP Reports
Briefly Noted

It’s Patient Safety Awareness Week
This week, March 10-16, is National Patient Safety Awareness Week. This is an excellent opportunity for members to showcase your patient safety quality improvement initiatives and successes, especially on social media.

The Institute for Healthcare Improvement (IHI) and the Society to Improve Diagnosis in Medicine will hold a Twitter chat, “Improving Diagnosis: A Foundation for Safe Care,” on March14 from 11 a.m.-12 p.m. (CT). Use #PSAW19 to participate in the conversation.

A variety of Patient Safety Awareness Week educational resources are available for download at no cost from IHI and the National Patient Safety Foundation.

On April 3 at the state capitol rotunda in Springfield, nearly 90 IHA member quality improvement projects will be on display for IHA’s Quality Advocacy Showcase. Patient safety is one of eight categories featured in the showcase.

IHA’s Midwest Alliance for Patient Safety (MAPS) Patient Safety Organization (PSO) offers healthcare providers the opportunity to work together to reduce serious events and patient harm within the federal confidentiality and privilege protections of the Patient Safety and Quality Improvement Act of 2005. On March 14, MAPS will hold a complimentary webinar, “Partners in Safety-Engaging Patients to Promote Safe Medication Use,” from 1-2 p.m. CT. More patient safety resources are accessible here. Learn more about MAPS and how to become a member here.

Through the Great Lakes Partners for Patients Hospital Improvement Innovation Network (HIIN) program, 130 participating IHA members are working to reduce hospital-acquired conditions by 20 percent and readmissions by 12 percent over the course of three years.

IDPH, CDC Issue Warning on Stem Cell Therapies
The Illinois Department of Public Health (IDPH), along with the Centers for Disease Control and Prevention (CDC), issued a warning to patients and healthcare providers last week about the risk of procedures involving unproven and non-Food and Drug Administration (FDA) approved stem cell therapies.

After an investigation of several bacterial infections in patients following the use of stem cell products from the ReGen Series® (distributed by Liveyon, LLC), an FDA investigation into the manufacturer, Genentech, found numerous deviations from established good practices and FDA guidelines, including screening stem cell donors for diseases such as HIV, hepatitis B, and hepatitis C infections.

While no bacterial infections occurring in Illinois residents following the use of these cells have been reported, IDPH is advising patients who received these cells since 2017 to talk with their healthcare providers about the need to be tested for HIV, hepatitis B virus, hepatitis C virus, and possibly other blood-borne infections.

Currently the only stem cell treatments approved by the FDA are products that treat certain cancers, blood disorders, and the immune system, and stem cell treatments that are part of a drug clinical trial.

IHA Issues Hospital-Specific VBP Reports
Yesterday, IHA made updated hospital-specific Medicare Value-Based Purchasing (VBP) program reports available to its member hospital CEOs, CFOs, CQOs and other finance staff via the IHA C-Suite. The reports include final results for 2018 and 2019, as well as estimates for 2020, based on CMS' third quarter 2018 update of its Hospital Compare website.

Briefly Noted
The Robert Wood Johnson Foundation (RWJF) has made available an interactive Opportunity Atlas that tracks the outcomes of 20 million Americans from childhood to their mid-30s in all 70,000 census tracts with the ability to analyze findings by race, gender, and income.  It also includes local data on educational level, housing costs, employment rates, incarceration, and teenage births.